US FDA Adcomm To Consider If Genentech’s Columvi Study Generalizable To US

 
• By Sue Sutter
  
China map
Did the large percentage of Chinese patients make the STARGLO study results inapplicable to the US? (Shutterstock)

More from US Advisory Committees

More from Product Reviews